Morphic reloads

Why Morphic raised an $80M B round to ramp up development of integrin inhibitors

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace.

Existing investor Omega Funds and new investor Novo Holdings A/S led the

Read the full 379 word article

How to gain access

Continue reading with a
two-week free trial.